Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms.

Blood - 21 Aug 2025

Arellano Nicole S, Heaton William L, Nauman Mirielle C, Runnels Abigail E, Gomez-Villa Jacky, Vanni Daniele, Gaviria Melissa, Fujita Maihi, Krah Nathan M, Ciboddo Michele, Yadav Saveg, Brown Callie T, Bowden Parker D, Chen Amy K, Henning Christopher, Catricalà Silvia, Casetti Ilaria Carola, Borsani Oscar, Rumi Elisa, Pietra Daniela, Plo Isabelle, Marty Caroline, Marchetti Marco, Patel Ami B, Saygin Caner, Elf Shannon E

Abstract excerpt

ABSTRACT: Most calreticulin (CALR) mutations in myeloproliferative neoplasms are classified as either type 1, a 52-base pair deletion (CALRdel52); or type 2, a 5-base pair insertion (CALRins5). Both are gain-of-function (GOF) mutations that generate an identical mutant C-terminal tail, which mediates the binding to, and activation of, the thrombopoietin receptor myeloproliferative leukemia protein (MPL). We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activating Transcription Factor 6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to bcl-X Protein

Share to Calreticulin

Share to Cell Line, Tumor

Share to Cell Survival

Share to Mutation

Share to Myeloproliferative Disorders

Share to Unfolded Protein Response

Source

Open in PubMed Open full text

Identifiers

PMID: 40403318
DOI: 10.1182/blood.2024026940
PMCID: PMC12982974

Genes

ATF6
CALR
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms.PMID 40403318Read ↗

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutantsSemantic proximity Read ↗

Mutant calreticulin in myeloproliferative neoplasmsSemantic proximity Read ↗

The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

Calreticulin mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN.Semantic proximity Read ↗

Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms.Semantic proximity Read ↗

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.Semantic proximity Read ↗

Targeting the CALR interactome in myeloproliferative neoplasmsSemantic proximity Read ↗

CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.Semantic proximity Read ↗

The Calreticulin gene and myeloproliferative neoplasms.Semantic proximity Read ↗

Calreticulin Mutations in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Mutant Calreticulin in the Myeloproliferative NeoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.